Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 02, 2019 01:30 ET | Source: Novartis Pharma AG

Sandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicine

Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1] More than 300,000 European men and women...
July 02, 2019 01:15 ET | Source: Novartis Pharma AG

Novartis highlights cognition data in secondary progressive multiple sclerosis (SPMS)

Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in...
July 01, 2019 11:30 ET | Source: Novartis Pharma AG

Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio

Basel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both...
July 01, 2019 01:30 ET | Source: Novartis Pharma AG

Novartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapies

Data from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures ...
July 01, 2019 01:15 ET | Source: Novartis Pharma AG

Novartis data underpin long-term efficacy of Aimovig® where other treatments have failed

Data from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive...
June 26, 2019 01:15 ET | Source: Novartis Pharma AG

Novartis highlights new publication showing IL-17A antibody Cosentyx® improves inflammation and rapidly suppresses IL-23 in plaque psoriasis

New data show that Cosentyx modulates gene expression leading to substantial improvement of inflammation, as early as Week 12 by reversing plaque histopathology in the majority of patients[1] ...
June 24, 2019 16:20 ET | Source: Novartis Pharma AG

Novartis provides update on phase 2b ENCORE-LF trial in NASH cirrhosis

Conatus today announced top-line results from the ENCORE-LF trial, which did not meet its primary endpoint Novartis remains fully committed to pursuing the development of multiple compounds in...
June 24, 2019 01:15 ET | Source: Novartis Pharma AG

Silvia Schweickart wird Vorsitzende der Geschäftsleitung der Novartis Pharma Schweiz AG in Rotkreuz

Rotkreuz, 24. Juni, 2019 - Silvia Schweickart übernimmt zum 1. Juli 2019 den Vorsitz der Geschäftsleitung der Novartis Pharma Schweiz AG und wird als Site Head auch für den gesamten Standort...
June 14, 2019 02:30 ET | Source: Novartis Pharma AG

Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001)

Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for...
June 12, 2019 01:20 ET | Source: Novartis Pharma AG

Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show

Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg[1] Data at 2 years demonstrate over 50% of adults with active...